Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
This important study, called Polaris-AD, is looking into a new treatment called AR1001 for people with early Alzheimer's disease. We're testing if this medicine is safe and if it can help slow down the disease's progression or improve symptoms. Participants will be randomly given either AR1001 or a placebo (a dummy medicine) without anyone knowing who gets what until the study ends. This is a common way to fairly test new medicines. Researchers believe AR1001 might work in several ways to tackle the underlying changes in the brain linked to Alzheimer's. The study aims to gather clear information that could help future treatments for this condition.
At a glance
What is this study about?
This study, called Polaris-AD, is a significant effort to find new ways to treat Alzheimer's disease. It's focused on people who are in the early stages of the condition. Many researchers around the world are working hard to understand Alzheimer's better and develop effective treatments, and this study is part of that important work.
The main goal is to test a new medicine called AR1001. We want to find out two key things: first, if AR1001 is safe for people to take, and second, if it can actually help with the symptoms of early Alzheimer's or slow down how quickly the disease progresses. When we say "early stages," we mean people who might have mild memory or thinking problems that are consistent with Alzheimer's disease, but are still able to manage most of their daily lives.
To make sure the study results are fair and accurate, it's set up so that some people will receive AR1001 and others will receive a 'placebo' – which looks like the real medicine but contains no active drug. Neither the participants nor the doctors will know who is getting which, and this is standard practice in medical research. AR1001 is thought to work in multiple ways within the brain to help deal with the changes caused by Alzheimer's. By comparing the groups, we can see if AR1001 made a real difference.
Key takeaways
- This study is testing a new medicine (AR1001) for early Alzheimer's disease.
- It aims to see if AR1001 is safe and effective in improving or slowing symptoms.
- Participants will receive either AR1001 or a dummy medicine (placebo).
- A study partner (e.g., family member) is required to help provide information.
- The study involves regular visits and careful monitoring of health and memory.
- You can withdraw from the study at any time without affecting your care.
Who may be eligible?
To be considered for this study, you would generally need to be a man or woman between 55 and 90 years old. You should also be experiencing mild memory or thinking problems that suggest early Alzheimer's disease, and these problems should have started within the last five years. Doctors will carry out tests to confirm that your symptoms match early Alzheimer's, including specific memory and overall thinking assessments.
An important part of eligibility is having clear evidence in your body that points to Alzheimer's disease. This is usually checked through special tests like a spinal fluid sample or a brain scan (PET scan) to look for certain protein changes in the brain linked to Alzheimer's. Also, it's very important to have a 'study partner' – someone like a family member or close friend who knows you well. This person would need to come to some appointments with you and be able to provide information about your memory, mood, and daily activities to the study team.
Finally, you would need to have had an MRI brain scan at some point that didn't show another clear reason for your memory problems. Everyone involved in the study must also be able to understand and sign a consent form, agreeing to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 55 and 90 years old?
- Have you experienced mild memory or thinking problems consistent with early Alzheimer's?
- Did these memory problems start within the last 5 years?
- Do you have a family member or close friend who could be your 'study partner'?
- Have you had tests (like a spinal fluid check or brain scan) that suggest Alzheimer's disease?
- Have you had a brain MRI scan that didn't show other causes for your memory issues?
What does participation involve?
If you decide to take part in this study, you'll be attending regular appointments at a clinic. At these visits, the study team will be checking your health, memory, and thinking abilities through various tests and questionnaires. You'll also be given the study medication (either AR1001 or the placebo) to take as prescribed. Your study partner will usually need to come with you to some of these appointments to help answer questions about your well-being and daily life. The study will continue over a significant period, but the exact total duration will be fully explained by the study team. You'll receive clear instructions on how to take the medicine and what to expect at each visit.
Potential risks and benefits
Locations (198)
- IMA Clinical Research PhoenixVerified postcodePhoenix, United States
- Perseverance Research Center, LLCVerified postcodeScottsdale, United States
- Clinical Endpoints - N. ScottsdaleVerified postcodeScottsdale, United States
- Banner Sun Health Research InstituteVerified postcodeSun City, United States
- Voyage MedicalVerified postcodeTempe, United States
- Sutter Health's Palo Alto Medical FoundationVerified postcodeBurlingame, United States
- Neuro-Pain Medical CenterVerified postcodeFresno, United States
- Fullerton Neurology and Headache CenterVerified postcodeFullerton, United States
- Esperanza ClinicalVerified postcodeMurrieta, United States
- Valley Clinical Trials, INCVerified postcodeNorthridge, United States
- Havana Research InstituteVerified postcodePasadena, United States
- Kaizen Brain CenterVerified postcodeSan Diego, United States
Common questions
What is Alzheimer's disease?
Alzheimer's disease is a condition that affects the brain, causing problems with memory, thinking, and daily activities, and usually gets worse over time.
What does 'early Alzheimer's disease' mean?
Early Alzheimer's means you have mild memory and thinking problems that are due to Alzheimer's disease, but you can still manage most of your everyday life.
What is a 'placebo'?
A placebo is a 'dummy' medicine that looks like the real medicine but contains no active drug. It's used in studies to fairly compare a new medicine's effects.
What is a 'study partner'?
A study partner is often a family member or close friend who knows you well and can provide helpful information to the study team about your daily life.
Will I know if I'm getting the real medicine or the placebo?
No, neither you nor your doctors will know whether you are receiving AR1001 or the placebo until the study has finished. This helps ensure fair results.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.